Omeros (OMER) Given a $24.00 Price Target by Maxim Group Analysts
A number of other research firms have also weighed in on OMER. Zacks Investment Research raised shares of Omeros from a sell rating to a hold rating in a research report on Wednesday, November 15th. Wedbush reissued an outperform rating and issued a $47.00 price objective on shares of Omeros in a research report on Tuesday, November 28th. HC Wainwright started coverage on shares of Omeros in a research report on Wednesday, November 8th. They issued a buy rating and a $30.00 price objective for the company. Finally, Cowen lowered shares of Omeros from an outperform rating to a market perform rating in a research report on Thursday, November 2nd. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $34.14.
Shares of Omeros (OMER) traded down $0.28 on Wednesday, reaching $19.42. 374,228 shares of the company’s stock were exchanged, compared to its average volume of 639,130. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. The firm has a market capitalization of $932.23, a PE ratio of -15.05 and a beta of 3.56. Omeros has a one year low of $8.71 and a one year high of $27.09.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The business had revenue of $21.66 million for the quarter, compared to analyst estimates of $17.82 million. The business’s revenue was up 91.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) EPS. research analysts predict that Omeros will post -0.98 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. First Interstate Bank purchased a new stake in Omeros during the third quarter worth approximately $108,000. Legal & General Group Plc grew its stake in Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares during the period. Hanseatic Management Services Inc. grew its stake in Omeros by 10,919.6% during the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Omeros during the third quarter worth approximately $256,000. Finally, SG Americas Securities LLC grew its stake in Omeros by 138.9% during the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 7,067 shares during the period. 49.71% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/01/07/omeros-omer-given-a-24-00-price-target-by-maxim-group-analysts.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.